glaucoma/obesity

FIELD OF THE INVENTION The present invention relates to salts of bicyclic, N-acylated imidazo-3-amines and imidazo-5-amines, to a process for producing them, to their use for producing pharmaceutical compositions and to pharmaceutical compositions containing these compounds. BACKGROUND OF THE

FIELD OF THE INVENTION The present invention relates to salts of bicyclic, N-acylated imidazo-3-amines and imidazo-5-amines, to a process for producing them, to their use for producing pharmaceutical compositions and to pharmaceutical compositions containing these compounds. BACKGROUND OF THE

BACKGROUND OF THE INVENTION This invention relates to cyclic amine phenyl .beta..sub.3 adrenergic receptor agonists useful for the treatment of metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis,

BACKGROUND OF THE INVENTION This invention relates to cyclic amine phenyl .beta..sub.3 adrenergic receptor agonists useful for the treatment of metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis,

BACKGROUND OF THE INVENTION This invention relates to azolidine derivatives which are .beta..sub.3 adrenergic receptor agonists useful for the treatment of metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis,

BACKGROUND OF THE INVENTION This invention relates to arylsulfide, arylsulfoxide and arylsulfone derivatives which are .beta..sub.3 adrenergic receptor agonists useful for the treatment of metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or

BACKGROUND OF THE INVENTION This invention relates to azolidine derivatives which are .beta..sub.3 adrenergic receptor agonists useful for the treatment of metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis,

FIELD OF THE INVENTION The present invention relates to novel thyroid receptor ligands and, more particularly, relates to novel oxamic acids, and derivatives thereof, which are useful in the treatment of obesity, hyperlipidemia, glaucoma, cardiac arrhythmia, skin disorders, thyroid disease,

FIELD OF THE INVENTION The present invention relates to novel thyroid receptor ligands and, more particularly, relates to novel oxamic acids, and derivatives thereof, which are useful in the treatment of obesity, hyperlipidemia, glaucoma, cardiac arrhythmia, skin disorders, thyroid disease,

ANGIOGENESIS In an adult, two types of blood vessels can potentially be found. The normal blood vessel is a resting, quiescent, fully developed vessel. A second form, a proliferating or developing blood vessel, occurs rarely during the normal human life cycle (occurring only in early development and

FIELD OF THE INVENTION The present invention is directed to alicyclic imidazoles which interact with the histamine H.sub.3 receptor as agonists, antagonists or inverse agonists; pharmaceutically active compositions containing such compounds; and the use of such compounds in formulations for the

FIELD OF THE INVENTION This invention relates to novel compounds which are thyroid receptor ligands, and are preferably selective for the thyroid hormone receptor .beta., and to methods of preparing such compounds and to methods for using such compounds such as in the regulation of

FIELD OF THE INVENTION This invention relates to novel compounds which are thyroid receptor ligands, and are preferably selective for the thyroid hormone receptor .beta., and to methods of preparing such compounds and to methods for using such compounds such as in the regulation of

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to new and improved inhibitors of Dipeptidyl-Peptidase-IV (DPP-IV) with beta blocker activity, and new and improved treatment methods and related uses. The inhibitors according to the invention are useful for

CROSS REFERENCE TO RELATED APPLICATIONS This application is a 371 of International Application No. PCT/EP2010/057598 filed Jun. 1, 2010. The invention relates to 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-- 2-ylamino)phenyl]-benzamide (also known as "imatinib"